Ethicon wraps up $3.4bn acquisition of robotic medical company Auris Health

Ethicon acquisition of Auris Health : Johnson & Johnson’s subsidiary Ethicon has wrapped up its previously announced $3.4 billion acquisition of California-based robotic medical company Auris Health. Ethicon acquisition of Auris Health Based on the achievement of certain predetermined milestones, the deal will see additional contingent payments More...

by pharmanewsdaily | Published 3 months ago
By pharmanewsdaily On Thursday, April 11th, 2019

US CDMO Brammer Bio to be acquired by Thermo Fisher

Thermo Fisher acquisition of Brammer Bio : Thermo Fisher Scientific, a global life sciences company, has agreed to buy US-based viral vector contract development and manufacturing organization (CDMO) Brammer Bio More...

By pharmanewsdaily On Wednesday, April 10th, 2019

Italian CDMO Olon wraps up acquisition of Mahad API plant in India

Mahad API plant acquisition : Olon, an Italy-based active pharmaceutical ingredients (API) developer and manufacturer, has completed the acquisition of an API manufacturing facility in Mahad in Maharashtra, India. The More...

By pharmanewsdaily On Tuesday, April 9th, 2019

Lilly teams up with ImmuNext for developing drugs for autoimmune diseases

US pharma giant Eli Lilly and Company (Lilly) and Lebanon-based ImmuNext have announced a global licensing and research collaboration for the development of drugs for the treatment of autoimmune diseases. Under More...

By Soujanya Ravi On Sunday, April 7th, 2019

Thermo Fisher to acquire viral vector CDMO Brammer Bio for $1.7bn

Global life sciences company Thermo Fisher Scientific has agreed to acquire Massachusetts-based Brammer Bio from Ampersand Capital Partners for about $1.7 billion in cash. Brammer Bio is a viral vector contract More...

By pharmanewsdaily On Sunday, April 7th, 2019

Arch Oncology raises $50m to advance anti-CD47 antibody therapies

Pharma industry news : Arch Oncology, a California-based clinical-stage immune-oncology company, has raised a funding of $50 million in a Series B financing round. The immune-oncology company is engaged in the discovery More...

By pharmanewsdaily On Sunday, April 7th, 2019

Merck to invest €150m to expand Aubonne biotech manufacturing site

Pharma giant Merck revealed its plans to invest €150 million in its Aubonne biotech manufacturing site in Switzerland to expand manufacturing capacity for its biotech medicines. The investment, which will be between More...

By pharmanewsdaily On Friday, April 5th, 2019

RepHresh brand rolls out RepHresh Cooling Relief Vaginal Anti-Itch Spray

The RepHresh brand has launched RepHresh Cooling Relief Vaginal Anti-Itch Spray in the US for women to get relief external vaginal itching and for neutralizing odor from the area. The RepHresh Cooling Relief Vaginal More...

By pharmanewsdaily On Wednesday, April 3rd, 2019

Novartis’ Mayzent approved by FDA for treatment of relapsing forms of MS

Mayzent FDA approval : The US Food and Drug Administration (FDA) has approved Swiss pharma company Novartis’ Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Mayzent More...

By pharmanewsdaily On Sunday, March 31st, 2019

Biogen to acquire UK gene therapy company Nightstar Therapeutics for $800m

Biogen acquisition of Nightstar Therapeutics : US biotech company Biogen has signed a deal of $800 million to acquire Nightstar Therapeutics, a British clinical-stage gene therapy company, as per the latest pharma More...